SYNEXUS FURTHER EXPANDS ITS GLOBAL FOOTPRINT WITH AN ACQUISITION IN SOUTH AFRICA

Synexus has expanded its global presence with the acquisition of a specialist clinical trial site close to Cape Town's international airport. This is its fourth dedicated research centre in South Africa and brings Synexus global site count to 24 with 3 new centres being opened in the last six months.

Synexus' continued global success is driving its international expansion. Its order book is at a record high and continuing to grow. The increased number of sites will ensure Synexus is able to continue to meet increasing demands from CROs and pharma.

The new Synexus site in South Africa is the Helderberg Clinical Trials Centre which has been in existence since 1994. It will now be known as the Synexus Helderberg Clinical Research Centre. Dr Graham Ellis who founded the Centre has been appointed Medical Director and will continue as the Centre Manager. Dr Ellis will continue to lead an unchanged investigator and clinical team.

Dr Ellis is considered an international expert in the field of diabetes and osteoporosis in South Africa and is often consulted locally and internationally by pharmaceutical companies. The Helderberg Centre has a strong track record of service performance and has completed over 150 clinical trials (including Phase 2 3 and 4 studies). The main areas of experience include diabetes osteoporosis COPD cardiovascular and infectious diseases.

Dr Christophe Berthoux CEO of Synexus says: "This is yet another new development that we have put in place to meet the increasing demands of the pharma industry for our high quality professional services. Our order book is at a record high and continuing to grow.

"We have long recognised the vital role South Africa has to play in global clinical trials as this addition to our portfolio and continued investment in the region is testament to that. South Africa provides access to a large patient pool excellent medical infrastructure and the training of the medical staff at all levels is of a very high standard. There is also a high public awareness of the benefits of clinical trials which speeds up recruitment and overcomes the lengthy regulatory process. These are all key factors in ensuring the success of a clinical trial."

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.